Department of Gynaecology, Shengjing Hospital of China Medical University, No.36 Sanhao Street, Heping District, Shenyang, 110004, China.
Department of ICU, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
J Ovarian Res. 2019 Aug 9;12(1):75. doi: 10.1186/s13048-019-0550-0.
The role of calcineurin/NFAT signaling in ovarian cancer has been unknown. NFAT was significantly overexpressed in ovarian cancer tissues and that overexpression of NFAT was significantly associated with metastasis and poor prognosis on clinical tissue level. To investigate whether NFAT upstream protein, calcineurin (CN), affects the prognosis in various histological subtype of ovarian cancer (OC).
The association between CN and clinical features was analyzed in 50 OC patients treated from 2007 to 2012. CN expression was examined using immunohistochemistry. We observed the association of CN expression with the prognosis in these patients.
CN expression was significantly increased in later-stage tumor tissue of serous carcinoma compared with those with early-stage. The expression of CN positively correlated with the serum cancer antigen 125 (CA125) level in ovarian clear-cell carcinoma and the serum alpha-fetoprotein (AFP) level in papillary serous cystadenocarcinoma. Particularly, higher CN expression in tumor tissues significantly correlated with reduced overall survival among patients with serous carcinoma. In addition, the serum cancer antigen 72-4 (CA72-4) level, serum carcinoembryonic antigen (CEA) levels, pathological stage, lymph node metastasis, and chemotherapeutic resistance were identified as significant prognostic factors in ovarian clear-cell carcinoma, serous carcinoma, or papillary serous cystadenocarcinoma.
CN is upregulated in ovarian cancer tissues with later-stage and that the expression of CN, CA72-4, and CEA was remarkably associated with poor prognosis in unique subtype of ovarian cancer. CN levels may be investigated for use as a prognostic biomarker for risk assessment in unique subtype of OC patients.
钙调神经磷酸酶/NFAT 信号通路在卵巢癌中的作用尚不清楚。NFAT 在卵巢癌组织中显著过表达，并且 NFAT 的过表达与临床组织水平的转移和预后不良显著相关。为了研究 NFAT 的上游蛋白钙调神经磷酸酶（CN）是否影响各种组织学亚型卵巢癌（OC）的预后。
分析了 2007 年至 2012 年间接受治疗的 50 例 OC 患者中 CN 与临床特征的关系。使用免疫组织化学检测 CN 的表达。我们观察了 CN 表达与这些患者预后的关系。
与早期肿瘤组织相比，CN 在浆液性癌晚期肿瘤组织中的表达显著增加。CN 的表达与卵巢透明细胞癌患者的血清癌抗原 125（CA125）水平和乳头状浆液性囊腺癌患者的血清甲胎蛋白（AFP）水平呈正相关。特别是，肿瘤组织中 CN 的高表达与浆液性癌患者总生存期的降低显著相关。此外，血清癌抗原 72-4（CA72-4）水平、血清癌胚抗原（CEA）水平、病理分期、淋巴结转移和化疗耐药被确定为卵巢透明细胞癌、浆液性癌或乳头状浆液性囊腺癌的显著预后因素。
CN 在晚期卵巢癌组织中上调，CN、CA72-4 和 CEA 的表达与卵巢癌独特亚型的不良预后显著相关。CN 水平可作为评估 OC 患者独特亚型风险的预后生物标志物进行研究。
